References
- Brenner D, Muller K, Wieland T, Weydt P, Bohm S, Lule D, et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain. 2016;139:e28.
- Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2016;48:1037–42.
- Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain. 2017;140:3081–104.
- Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436–41.
- Nguyen HP, Van Mossevelde S, Dillen L, De Bleecker JL, Moisse M, Van Damme P, et al. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Neurobiol Aging. 2018;61:255 e1–e7.
- Wang J, Van Damme P, Cruchaga C, Gitcho MA, Vidal JM, Seijo-Martinez M, et al. Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem. 2010;112:1305–15.
- Redaelli V, Rossi G, Maderna E, Kovacs GG, Piccoli E, Caroppo P, et al. Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (TAR DNA-binding protein 43 inclusions) in missense progranulin mutation Cys139Arg. Brain Pathol. 2018;28:72–6.
- Naruse H, Ishiura H, Mitsui J, Takahashi Y, Matsukawa T, Tanaka M, et al. Burden of rare variants in causative genes for amyotrophic lateral sclerosis (ALS) accelerates age at onset of ALS. J Neurol Neurosurg Psychiatry. 2019;90:537–42.
- Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 2008;71:656–64.
- Piaceri I, Pradella S, Cupidi C, Nannucci S, Polito C, Bagnoli S, et al. Association of the variant Cys139Arg at GRN gene to the clinical spectrum of frontotemporal lobar degeneration. J Alzheimers Dis. 2014;40:679–85.